• Loading stock data...
Est. 2004

Thursday 03/7/2019

We release small market news updates daily, 5 times a week! Always check back to get the inside scoop on what going on.


Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More


  • 7:14 AM

    NORTHVALE, N.J., May 31, 2017, ELTP, (GLOBE NEWSWIRE) — Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCBB:ELTP) announced today the issuance of European Patent No. 1615623 titled “Abuse-Resistant Oral Dosage Forms and Method of Use Thereof” issued March 22, 2017. This patent expands the intellectual property for the Company’s opioid abuse deterrent technology. Elite now has four US patents, one European patent, and two Canadian patents issued in this area with additional patents pending in the U.S., Canada and Europe.

    Read more
  • 1:49 PM

    NORTHVALE, N.J, Jan. 17, 2017, ELTP, (GLOBE NEWSWIRE) — Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCBB:ELTP) today reported positive topline results from a pivotal bioequivalence fed study initiated in November 2016.  The topline results indicate that Elite’s generic product is bioequivalent to the branded product, OxyContin® (extended release Oxycodone Hydrochloride). A fasted study was previously conducted in September 2016, also with positive results. The study was a single dose crossover comparative bioavailability study of Oxycodone HCl extended release in

    Read more
Public Wire Banner